Related Experiment Video
Updated: Oct 10, 2025
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Antitumor Effect of Sclerostin against Osteosarcoma
Hirokazu Ideta1, Kazushige Yoshida1, Masanori Okamoto1
1Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.
Abstract:
Various risk factors and causative genes of osteosarcoma have been reported in the literature; however, its etiology remains largely unknown. Bone formation is a shared phenomenon in all types of osteosarcomas, and sclerostin is an extracellular soluble factor secreted by osteocytes that prevents bone formation by inhibiting the Wnt signaling pathway. We aimed to investigate the antitumor effect of sclerostin against osteosarcoma. Osteosarcoma model mice were prepared by transplantation into the dorsal region of C3H/He and BALB/c-nu/nu mice using osteosarcoma cell lines LM8 (murine) and 143B (human), respectively. Cell proliferations were evaluated by using alamarBlue and scratch assays. The migratory ability of the cells was evaluated using a migration assay. Sclerostin was injected intraperitoneally for 7 days to examine the suppression of tumor size and extension of survival. The administration of sclerostin to osteosarcoma cells significantly inhibited the growth and migratory ability of osteosarcoma cells. Kaplan-Meier curves and survival data demonstrated that sclerostin significantly inhibited tumor growth and improved survival. Sclerostin suppressed the proliferative capacity and migratory ability of osteosarcoma cells. Osteosarcoma model mice inhibited tumor growth and prolonged survival periods by the administration of sclerostin. The effect of existing anticancer drugs such as doxorubicin should be investigated for future clinical applications.
Insights
Sclerostin effectively inhibits osteosarcoma cell growth and migration. This study demonstrates sclerostin
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma etiology is largely unknown despite identified risk factors and genes.
- Bone formation is characteristic of osteosarcomas.
- Sclerostin, an osteocyte-secreted factor, inhibits bone formation via Wnt signaling antagonism.
Purpose of the Study:
- To investigate the potential antitumor effects of sclerostin in osteosarcoma.
- To evaluate sclerostin's impact on osteosarcoma cell proliferation and migration.
- To assess sclerostin's efficacy in reducing tumor growth and extending survival in vivo.
Main Methods:
- Osteosarcoma mouse models were established using LM8 and 143B cell lines.
- Cell proliferation was assessed using alamarBlue and scratch assays.
- Cell migration was evaluated via migration assays; sclerostin was administered intraperitoneally to mice.
Main Results:
- Sclerostin administration significantly inhibited osteosarcoma cell proliferation and migration in vitro.
- In vivo studies showed sclerostin suppressed tumor growth and prolonged survival periods in mice.
- Kaplan-Meier analysis confirmed sclerostin's positive impact on survival data.
Conclusions:
- Sclerostin demonstrates significant antitumor properties against osteosarcoma by suppressing proliferation and migration.
- Sclerostin treatment in mouse models led to reduced tumor burden and extended survival.
- Further research into combining sclerostin with existing therapies like doxorubicin is warranted for clinical applications.
